ホーム>>Signaling Pathways>> Others>>Trombodipine (PCA-4230)

Trombodipine (PCA-4230) (Synonyms: PCA-4230)

カタログ番号GC32610

トロンボジピン (PCA-4230) は、抗血栓剤です。

Products are for research use only. Not for human use. We do not sell to patients.

Trombodipine (PCA-4230) 化学構造

Cas No.: 113658-85-8

サイズ 価格 在庫数 個数
1mg
$690.00
在庫あり
5mg
$1,105.00
在庫あり
10mg
$1,767.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com


顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Trombodipine is an antithrombotic agent.

Trombodipine is an antithrombotic agent. Exposure to 50 μM Trombodipine reveals an important stasis of growth. The percentage of inhibition exerted by 1 μM Trombodipine on day 3, 5 and 7 of the growth curve is 22.0±4.5, 32.0±3.0 and 29.4±6.0%, respectively (P<0.05). The inhibitory effect of Trombodipine on cell proliferation is reversible and after removal of Trombodipine the proliferation of the cells is resumed[1]. Addition of Trombodipine reduces cell number in a dose-dependent manner over a period of 4 to 6 days in culture. When compare to control cultures at the latest time points investigated, 5 μM Trombodipine decreases the number of E19P cells and human VSMCs by 25 and 21%, respectively, whereas 50 μM Trombodipine reduces E19P and human VSMC number by 85 and 74%, respectively[2].

[1]. del Rio M, et al. Antiproliferative effects of PCA-4230, a new antithrombotic drug, in vascular smooth muscle cells. Br J Pharmacol. 1997 Apr;120(7):1360-6.

レビュー

Review for Trombodipine (PCA-4230)

Average Rating: 5 ★★★★★ (Based on Reviews and 10 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Trombodipine (PCA-4230)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.